# Current and future role of neoadjuvant therapy for breast cancer.

**Autores:** Untch M, Konecny GE, Paepke S et al.
**Revista:** Breast (2014)
**PMID:** 25034931 | **PMCID:** —
**DOI:** [10.1016/j.breast.2014.06.004](https://doi.org/10.1016/j.breast.2014.06.004)
**Fuente:** PubMed (abstract only — full text vía DOI)

## Relevancia
Aporta evidencia sobre la respuesta axilar y la factibilidad de cirugía axilar conservadora en cáncer de mama inflamatorio tratado con NAC, contexto clásicamente excluido de los estudios de SLNB.

## Abstract
Neoadjuvant systemic chemotherapy is a possible therapeutic approach for the treatment of locally advanced operable, primarily non-operable or inflammatory breast cancer. Neoadjuvant systemic chemotherapy is an option for breast cancer patients who would require adjuvant chemotherapy otherwise based on clinical and histological examination and imaging. The use of neoadjuvant systemic therapy in operable breast cancer is currently increasing because of its advantages that include higher rates of breast conserving surgery and the possibility of measuring early in-vivo response to systemic treatment. The timing of axillary sentinel lymph node diagnosis (i.e. before or after neoadjuvant chemotherapy) is critical in that it may influence the likelihood of axillary preservation. It is not yet clear if neoadjuvant therapy might improve outcomes in certain subgroups of breast cancer patients. Neoadjuvant treatment modalities require a close collaboration between oncology professionals, including surgeons, gynecologists, medical oncologists, radiation oncologists, radiologists and pathologists. The most important parameter for treatment success and improved overall survival is the achievement of a pathologic complete response (pCR), although the role of pCR in patients with luminal A like tumours might be less informative. Identification of patient subgroups with high pCR rates may allow less invasive surgical or radiological interventions. Patients not achieving a pCR may be candidates for postoperative clinical trials exploring novel systemic treatments.

## Acceso
Vía [DOI](https://doi.org/10.1016/j.breast.2014.06.004) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1016/j.breast.2014.06.004*
